

In the Claims:

1. (Withdrawn-currently amended) An isolated nucleic acid molecule selected from the group consisting of:
 - (a) nucleic acid molecules encoding T128 polypeptide (SEQ ID NO: 1), or a polypeptide with at least 80% identical 90% sequence identity to SEQ ID NO: 1, or a fragment thereof, which is capable of cross reacting with sera from patients with prostate cancer;
 - (b) nucleic acid molecules comprising the nucleotide sequence between nucleic acid residues 642 and 1688 of SEQ ID NO: 2;
 - (c) nucleic acid molecules, the complementary strand of which hybridizes under conditions of high stringency specifically hybridises to a nucleic acid molecule in (a) or (b); and
 - (d) nucleic acid molecules with at least 95% sequence identity to a nucleic acid molecule in (a) or (b).
 - (d) nucleic acid molecules the sequence of which differs from the sequence of the nucleic acid molecule in (a), (b), or (c) due to the degeneracy of the genetic code.
2. (Withdrawn) An isolated nucleic acid molecule according to claim 1, encoding the polypeptide sequence of SEQ ID NO: 1.
3. (Withdrawn-currently amended) An isolated nucleic acid molecule which is at least 80% homologous to the nucleic acid molecule according to claim 1 and which encodes a polypeptide which is expressed in higher concentrations in cancerous tissue compared to that tissue when in a normal state.
4. (Withdrawn-currently amended) An isolated nucleic acid molecule comprising at least 15 consecutive nucleic acids capable of specifically hybridising hybridizing under conditions of high stringency to a sequence within a nucleic acid molecule according to claim 1.
5. (Withdrawn) A vector comprising a nucleic acid molecule according to claim 1.
6. (Withdrawn) A host cell comprising a vector according to claim 5.

7. (Currently amended) An isolated protein polypeptide comprising consisting essentially of an amino acid sequence ~~encoded by a nucleic acid molecule according to claim 1, selected from the group consisting of:~~

(a) T128 polypeptide (SEQ ID NO: 1);

(b) a polypeptide with at least 90% sequence identity to SEQ 1D NO: 1;

(c) a polypeptide encoded by the nucleic acid sequence between nucleic acid residues 642 and 1688 of SEQ 1D NO: 2;

(d) a polypeptide encoded by a nucleic acid molecule with at least 95% sequence identity to the nucleic acid sequence between nucleic acid residues 642 and 1688 of SEQ 1D NO: 2;

(e) a polypeptide encoded by a nucleic acid molecule, the complementary strand of which hybridizes under conditions of high stringency to the nucleic acid molecule in (c) or (d) or the nucleic acid molecule encoding the polypeptide in (a) or (b).

8. (Currently Amended) An isolated protein polypeptide according to claim 7 which ~~comprises-~~ consists essentially of the amino acid sequence of SEQ 1D NO: 1.

9. (Canceled)

10. (Withdrawn-currently amended) ~~A monoclonal An~~ antibody capable of specifically binding to ~~the polypeptide the protein~~ of claim 7, or a fragment or derivative thereof.

11.-12. (Canceled)

13. (Withdrawn) A method of detecting or monitoring cancer in a patient comprising the step of detecting or monitoring elevated levels of a nucleic acid molecule comprising the nucleic acid molecule according to claim 1 in a sample from the patient.

14. (Withdrawn) A method of detecting or monitoring cancer comprising the step of detecting or monitoring elevated levels of a nucleic acid molecule comprising the nucleic acid molecule according to claim 1 in combination with a reverse transcription polymerase chain reaction.

15. (Withdrawn-currently amended) A method of detecting or monitoring cancer comprising the step of detecting or monitoring elevated levels of the protein polypeptide according to claim 7.

16. (Withdrawn-currently amended) The method according to claim 15 wherein the detecting or monitoring step includes a monoclonal an antibody selective for and capable of detecting the protein polypeptide.

17. (Withdrawn) The method according to claim 16 wherein the detecting or monitoring step includes an Enzyme-Linked ImmunoSorbant Assay.

18. (Withdrawn) The method according to claim 13 wherein the cancer is a gastro-intestinal cancer, kidney cancer or a prostate cancer.

19. (Withdrawn) A kit comprising the nucleic acid molecule as defined in claim 1 for use with a method of detecting or monitoring cancer.

20. (Withdrawn) A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of a nucleic acid molecule comprising the nucleic acid molecule according to claim 1 or a pharmaceutically effective fragment thereof.

21. (Withdrawn-currently amended) A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of a nucleic acid molecule which hybridizes under conditions of high stringency hybridisable under high stringency conditions to a nucleic acid molecule comprising the nucleic acid molecule according to claim 1 or a pharmaceutically effective fragment thereof.

22. (Withdrawn-currently amended) A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of the protein polypeptide according to claim 7 or a pharmaceutically effective fragment thereof.

23. (Withdrawn-currently amended) A method of prophylaxis or treatment of cancer comprising the step of administering to a patient a pharmaceutically effective amount of the monoclonal antibody according to claim 10.

24. (Withdrawn) The method according to claim 20 wherein the cancer is a gastro-intestinal cancer.

25. (Withdrawn) A vaccine comprising a nucleic acid molecule comprising the nucleic acid molecule according to claim 1 or a pharmaceutically effective fragment thereof, and a pharmaceutically acceptable carrier.

26. (Canceled)

27. (Previously presented) The polypeptide according to claim 7 or a pharmaceutically effective fragment thereof, attached to a carrier protein.

28. (Currently amended) A kit comprising the protein a reagent for detecting the polypeptide according to claim 7 for use with a method of detecting or monitoring cancer.

29. (Withdrawn-currently amended) A kit comprising the monoclonal antibody according to claim 10 for use with a method of detecting or monitoring cancer.

30. (Withdrawn) An immunogenic composition comprising a nucleic acid molecule comprising the nucleic acid molecule according to claim 1 or a pharmaceutically effective fragment thereof, and a pharmaceutically acceptable carrier.

31. (Currently amended) An immunogenic composition comprising the protein polypeptide according to claim 7 or a pharmaceutically effective fragment thereof, and a pharmaceutically acceptable carrier.

32. (Not entered)
33. (Not entered)
34. (New) The antibody of claim 10 wherein the antibody is monoclonal.
35. (New) The antibody of claim 10 wherein the antibody is polyclonal.